Inovio Pharmaceuticals Company Profile (NASDAQ:INO)

About Inovio Pharmaceuticals (NASDAQ:INO)

Inovio Pharmaceuticals logoInovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company's DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology & Medical Research - NEC
  • Sub-Industry: N/A
  • Symbol: NASDAQ:INO
  • CUSIP: N/A
  • Web: www.inovio.com
Capitalization:
  • Market Cap: $535.4 million
  • Outstanding Shares: 90,134,000
Average Prices:
  • 50 Day Moving Avg: $7.60
  • 200 Day Moving Avg: $6.91
  • 52 Week Range: $5.50 - $11.00
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -4.05
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $37.63 million
  • Price / Sales: 13.20
  • Book Value: $1.42 per share
  • Price / Book: 3.88
Profitability:
  • EBIDTA: ($80,300,000.00)
  • Net Margins: -235.91%
  • Return on Equity: -65.97%
  • Return on Assets: -48.95%
Debt:
  • Current Ratio: 2.67%
  • Quick Ratio: 2.67%
Misc:
  • Average Volume: 1.95 million shs.
  • Beta: 2.85
  • Short Ratio: 7.34
 
Frequently Asked Questions for Inovio Pharmaceuticals (NASDAQ:INO)

What is Inovio Pharmaceuticals' stock symbol?

Inovio Pharmaceuticals trades on the NASDAQ under the ticker symbol "INO."

When did Inovio Pharmaceuticals' stock split? How did Inovio Pharmaceuticals' stock split work?

Inovio Pharmaceuticals shares reverse split before market open on Friday, June 6th 2014. The 1-4 reverse split was announced on Friday, May 23rd 2014. The number of shares owned by shareholders was adjusted after the market closes on Thursday, June 5th 2014. An investor that had 100 shares of Inovio Pharmaceuticals stock prior to the reverse split would have 25 shares after the split.

How were Inovio Pharmaceuticals' earnings last quarter?

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced its quarterly earnings results on Wednesday, May, 10th. The company reported ($0.31) earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of ($0.31). The firm earned $10.40 million during the quarter, compared to the consensus estimate of $5.83 million. Inovio Pharmaceuticals had a negative net margin of 235.91% and a negative return on equity of 65.97%. The business's revenue was up 28.4% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.11) EPS. View Inovio Pharmaceuticals' Earnings History.

Where is Inovio Pharmaceuticals' stock going? Where will Inovio Pharmaceuticals' stock price be in 2017?

9 analysts have issued twelve-month price targets for Inovio Pharmaceuticals' stock. Their forecasts range from $11.00 to $40.00. On average, they anticipate Inovio Pharmaceuticals' share price to reach $22.11 in the next year. View Analyst Ratings for Inovio Pharmaceuticals.

What are analysts saying about Inovio Pharmaceuticals stock?

Here are some recent quotes from research analysts about Inovio Pharmaceuticals stock:

  • 1. According to Zacks Investment Research, "Inovio is a development-stage biopharmaceutical company is focused on the development of treatments targeting various forms of cancer and infectious diseases. We are pleased with the company’s collaborations with other firms for pipeline development. Shares of Inovio have outperformed the Medical-Biomedical/Genetics industry so far this year. However, Inovio suffered a setback with the FDA placing clinical hold on the proposed phase III program on its lead pipeline candidate, VGX-3100 in Oct 2016. Though in Apr 2017, Inovio submitted a complete response to the FDA for the initiation of the study, FDA decision is still pending. Estimates have been going up lately ahead of the company’s Q2 earnings release. The company has negative record of earnings surprises in recent quarters." (7/11/2017)
  • 2. Maxim Group analysts commented, "Inovio announced a collaboration with Roche (RHHBY – $34.10 – NR) to evaluate their DNA-based immunotherapies INO-5401 (multiple cancer antigens) and INO-9012 (IL-12 immune stimulator) with Tecentriq (PD-L1 checkpoint) in advanced bladder cancer." (6/1/2017)

Who are some of Inovio Pharmaceuticals' key competitors?

Who are Inovio Pharmaceuticals' key executives?

Inovio Pharmaceuticals' management team includes the folowing people:

  • Jong Joseph Kim Ph.D., President, Chief Executive Officer, Director
  • Peter D. Kies, Chief Financial Officer
  • Niranjan Y. Sardesai Ph.D., Chief Operating Officer
  • Mark L. Bagarazzi M.D., Chief Medical Officer
  • Avtar S. Dhillon M.D., Non-Executive Chairman of the Board
  • George W. Bickerstaff III, Director
  • David B. Weiner, Director
  • Simon X. Benito, Independent Director
  • Angel Cabrera Ph.D., Independent Director

Who owns Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Round Table Services LLC (0.17%), Russell Investments Group Ltd. (0.07%), Private Capital Advisors Inc. (0.05%), ING Groep NV (0.02%) and First Financial Bank Trust Division (0.02%). Company insiders that own Inovio Pharmaceuticals stock include David B Weiner, Jong Joseph Kim, Morton Collins, Niranjan Sardesai and Simon X Benito. View Institutional Ownership Trends for Inovio Pharmaceuticals.

Who sold Inovio Pharmaceuticals stock? Who is selling Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including ING Groep NV and Russell Investments Group Ltd.. Company insiders that have sold Inovio Pharmaceuticals stock in the last year include David B Weiner, Jong Joseph Kim and Niranjan Sardesai. View Insider Buying and Selling for Inovio Pharmaceuticals.

Who bought Inovio Pharmaceuticals stock? Who is buying Inovio Pharmaceuticals stock?

Inovio Pharmaceuticals' stock was purchased by a variety of institutional investors in the last quarter, including Private Capital Advisors Inc.. Company insiders that have bought Inovio Pharmaceuticals stock in the last two years include Morton Collins, Niranjan Sardesai and Simon X Benito. View Insider Buying and Selling for Inovio Pharmaceuticals.

How do I buy Inovio Pharmaceuticals stock?

Shares of Inovio Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Inovio Pharmaceuticals' stock price today?

One share of Inovio Pharmaceuticals stock can currently be purchased for approximately $5.51.


MarketBeat Community Rating for Inovio Pharmaceuticals (NASDAQ INO)
Community Ranking:  3.5 out of 5 (   )
Outperform Votes:  267 (Vote Outperform)
Underperform Votes:  111 (Vote Underperform)
Total Votes:  378
MarketBeat's community ratings are surveys of what our community members think about Inovio Pharmaceuticals and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Inovio Pharmaceuticals (NASDAQ:INO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Hold Ratings, 7 Buy Ratings
Consensus Rating:Buy (Score: 2.78)
Consensus Price Target: $22.11 (301.29% upside)

Analysts' Ratings History for Inovio Pharmaceuticals (NASDAQ:INO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
7/27/2017HC WainwrightSet Price TargetBuy$13.00HighView Rating Details
7/18/2017AegisReiterated RatingBuy$14.00LowView Rating Details
6/8/2017Maxim GroupSet Price TargetBuy$12.00HighView Rating Details
6/8/2017Piper Jaffray CompaniesUpgradeNeutral -> Overweight$14.00MediumView Rating Details
5/25/2017Stifel NicolausReiterated RatingBuy$11.00HighView Rating Details
5/1/2017NomuraReiterated RatingBuy$40.00LowView Rating Details
5/1/2017Jefferies Group LLCReiterated RatingNeutral$38.00LowView Rating Details
5/1/2017BNP ParibasReiterated RatingNeutral$39.00LowView Rating Details
10/4/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
6/21/2016Rodman & RenshawReiterated RatingBuy$17.00N/AView Rating Details
(Data available from 7/28/2015 forward)

Earnings

Earnings History for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Earnings History by Quarter for Inovio Pharmaceuticals (NASDAQ INO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/10/2017Q1 2017($0.31)($0.31)$5.83 million$10.40 millionViewN/AView Earnings Details
3/15/2017Q4 2016($0.29)($0.35)$5.21 million$8.50 millionViewN/AView Earnings Details
11/9/2016Q316($0.26)($0.28)$5.16 million$12.54 millionViewListenView Earnings Details
8/8/2016Q2($0.21)($0.26)$4.95 million$6.20 millionViewN/AView Earnings Details
5/9/2016Q1($0.14)($0.11)$4.75 million$8.10 millionViewN/AView Earnings Details
3/14/2016Q4($0.20)($0.25)$6.96 million$5.94 millionViewListenView Earnings Details
11/9/2015Q3$0.04$0.07$1.84 million$24.18 millionViewN/AView Earnings Details
8/10/2015Q215($0.13)($0.10)$5.52 million$5.30 millionViewListenView Earnings Details
5/11/2015Q1($0.11)($0.18)$7.04 million$5.20 millionViewListenView Earnings Details
3/16/2015Q414($0.10)($0.12)$5.24 million$2.50 millionViewN/AView Earnings Details
11/10/2014Q314($0.11)($0.12)$5.60 million$1.80 millionViewN/AView Earnings Details
8/11/2014Q214($0.17)($0.19)$1.80 million$3.80 millionViewN/AView Earnings Details
5/12/2014Q114($0.04)($0.05)$1.41 million$2.40 millionViewN/AView Earnings Details
3/17/2014Q413($0.03)($0.04)$1.36 million$1.70 millionViewN/AView Earnings Details
11/11/2013Q3($0.02)($0.16)$2.99 million$9.50 millionViewListenView Earnings Details
11/7/2012Q312($0.05)($0.05)$2.07 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Inovio Pharmaceuticals (NASDAQ:INO)
Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-1.36 EPS

Dividends

Dividend History for Inovio Pharmaceuticals (NASDAQ:INO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Ownership Percentage: 10.60%
Institutional Ownership Percentage: 27.77%
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Institutional Ownership by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Insider Trades by Quarter for Inovio Pharmaceuticals (NASDAQ:INO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/25/2017David B WeinerDirectorSell8,000$8.00$64,000.00View SEC Filing  
3/31/2017Jong Joseph KimCEOSell147,180$6.54$962,557.20View SEC Filing  
3/27/2017Morton CollinsDirectorBuy21,300$6.25$133,125.00View SEC Filing  
8/29/2016Niranjan SardesaiCOOSell21,800$9.30$202,740.00View SEC Filing  
6/28/2016Morton CollinsDirectorBuy10,000$9.13$91,300.00View SEC Filing  
5/18/2016Simon X BenitoDirectorSell6,250$10.37$64,812.50View SEC Filing  
4/15/2016Morton CollinsDirectorBuy68,400$9.52$651,168.00View SEC Filing  
9/30/2015Niranjan SardesaiCOOBuy4,000$5.50$22,000.00View SEC Filing  
8/14/2015Simon X BenitoDirectorBuy6,000$7.21$43,260.00View SEC Filing  
4/13/2015Angel CabreraDirectorBuy8,000$9.53$76,240.00View SEC Filing  
10/9/2014Peter KiesCFOBuy3,960$10.10$39,996.00View SEC Filing  
8/21/2014Morton CollinsDirectorBuy8,000$10.01$80,080.00View SEC Filing  
8/20/2014Morton CollinsDirectorBuy40,600$9.74$395,444.00View SEC Filing  
8/12/2014Jong Joseph KimCEOBuy250,000$9.06$2,265,000.00View SEC Filing  
8/12/2014Niranjan SardesaiCOOBuy2,550$8.70$22,185.00View SEC Filing  
4/15/2014Jong Joseph KimCEOBuy25,000$2.25$56,250.00View SEC Filing  
11/13/2013Morton CollinsDirectorBuy254,500$1.82$463,190.00View SEC Filing  
4/16/2013Mark BagarazziInsiderBuy60,000$0.56$33,600.00View SEC Filing  
4/2/2013Jong Joseph KimCEOBuy90,000$0.50$45,000.00View SEC Filing  
3/22/2013Angel CabreraDirectorBuy40,000$0.54$21,600.00View SEC Filing  
3/20/2013Jong Joseph KimCEOBuy60,000$0.53$31,800.00View SEC Filing  
3/20/2013Niranjan SardesaiCOOBuy25,000$0.53$13,250.00View SEC Filing  
1/15/2013Morton CollinsDirectorBuy100,000$0.67$67,000.00View SEC Filing  
11/14/2012Austin W & Greenhouse Da MarxeMajor ShareholderSell622,550$0.53$329,951.50View SEC Filing  
8/15/2012Angel CabreraDirectorBuy75,000$0.59$44,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Inovio Pharmaceuticals (NASDAQ:INO)
Latest Headlines for Inovio Pharmaceuticals (NASDAQ:INO)
Source:
DateHeadline
nasdaq.com logoInovio Pharmaceuticals to Report Second Quarter 2017 Financial ... - Nasdaq
www.nasdaq.com - July 28 at 3:47 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) Given a $13.00 Price Target at HC Wainwright
www.americanbankingnews.com - July 27 at 10:34 AM
globenewswire.com logoInovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017 - GlobeNewswire (press release)
globenewswire.com - July 26 at 8:09 PM
finance.yahoo.com logoInovio Pharmaceuticals to Report Second Quarter 2017 Financial Results on August 8, 2017
finance.yahoo.com - July 26 at 8:09 PM
finance.yahoo.com logoInovio Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : INO-US : July 20, 2017
finance.yahoo.com - July 21 at 9:03 PM
bizjournals.com logoMontco immunotherapy company prices $75M stock sale - Philadelphia Business Journal
www.bizjournals.com - July 20 at 11:43 PM
thestreet.com logoBiotech Movers: Sarepta, Inovio, Mylan - TheStreet.com
www.thestreet.com - July 20 at 11:43 PM
fool.com logoWhy MarineMax, Inovio Pharmaceuticals, and Check Point Software Technologies Slumped Today - Motley Fool
www.fool.com - July 20 at 11:43 PM
nasdaq.com logoBUZZ-US STOCKS ON THE MOVE- IBM, Vertex Pharma, WW Grainger, Scripps Networks, Morgan Stanley - Nasdaq
www.nasdaq.com - July 20 at 3:17 AM
nasdaq.com logoInovio Announces Pricing of Public Offering of Common Stock - Nasdaq
www.nasdaq.com - July 20 at 3:17 AM
fool.com logoHere's Why Inovio Pharmaceuticals, Inc. Stock Fell Today - Motley Fool
www.fool.com - July 20 at 3:17 AM
reuters.com logoBRIEF-Inovio Pharmaceuticals says co has about $92 mln of cash and cash equivalents and short-term investments - SEC Filing
www.reuters.com - July 19 at 10:15 PM
finance.yahoo.com logoToday's Research Reports on Trending Tickers: Inovio Pharmaceuticals Inc. and Universal Display Corporation
finance.yahoo.com - July 19 at 10:15 PM
finance.yahoo.com logoBiotech Movers: Vertex Continues to Move on Data for CF Regimen
finance.yahoo.com - July 19 at 10:15 PM
finance.yahoo.com logoHere's Why Inovio Pharmaceuticals, Inc. Stock Fell Today
finance.yahoo.com - July 19 at 10:15 PM
finance.yahoo.com logoInovio Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - July 19 at 10:15 PM
globenewswire.com logoInovio Announces Proposed Public Offering of Common Stock - GlobeNewswire (press release)
globenewswire.com - July 19 at 7:04 AM
americanbankingnews.com logoInovio Pharmaceuticals' (NASDAQ:INO) Buy Rating Reaffirmed at Aegis
www.americanbankingnews.com - July 18 at 1:19 PM
streetinsider.com logoInovio Pharmaceuticals, Inc. - StreetInsider.com
www.streetinsider.com - July 16 at 11:57 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Rating Increased to Buy at Zacks Investment Research
www.americanbankingnews.com - July 11 at 4:52 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Given Consensus Recommendation of "Buy" by Analysts
www.americanbankingnews.com - July 10 at 8:31 PM
finance.yahoo.com logoBiotech Movers: Exelixis, Omeros, Inovio
finance.yahoo.com - July 10 at 7:53 PM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (NASDAQ:INO) PT Set at $13.00 by HC Wainwright
www.americanbankingnews.com - July 7 at 6:56 PM
rttnews.com logoInovio's Monoclonal Antibody Platform Achieves Proof-of-Principle Validation
www.rttnews.com - July 7 at 6:28 AM
finance.yahoo.com logoInovio’s DNA-based Monoclonal Antibody Platform Achieves Further Proof-of-Principle Validation
finance.yahoo.com - July 7 at 6:28 AM
americanbankingnews.com logo Brokerages Anticipate Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Will Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - July 6 at 12:32 AM
americanbankingnews.com logo Brokerages Anticipate Inovio Pharmaceuticals, Inc. (INO) to Announce -$0.19 Earnings Per Share
www.americanbankingnews.com - July 6 at 12:32 AM
prnewswire.com logoProstate Specific Antigen Pipeline Therapeutics Development Review H1 2017 Says a New Research Report at RnRMarketResearch.com
www.prnewswire.com - June 22 at 11:12 PM
nasdaq.com logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - Nasdaq
www.nasdaq.com - June 21 at 3:37 PM
globenewswire.com logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention - GlobeNewswire (press release)
globenewswire.com - June 20 at 2:57 AM
finance.yahoo.com logoInovio Pharmaceuticals to Participate on Panel at 2017 BIO International Convention
finance.yahoo.com - June 19 at 12:21 PM
streetinsider.com logoInovio Pharma (INO) Completes Enrollment for Second Zika Vaccine Phase 1 Trial with 160 Subjects in Puerto Rico
www.streetinsider.com - June 16 at 5:27 AM
finance.yahoo.com logoInovio Fully Enrolls 160 Subjects in Puerto Rico for Second Zika Vaccine Phase 1 Trial; Continues Leadership to Advance an Effective Preventive Solution
finance.yahoo.com - June 16 at 5:26 AM
finance.yahoo.com logoWhy Is Inovio (INO) Up 21.3% Since the Last Earnings Report?
finance.yahoo.com - June 14 at 11:22 AM
americanbankingnews.com logoInovio Pharmaceuticals, Inc. (INO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - June 13 at 8:52 PM
finance.yahoo.com logo3 Stocks That Could Put Amazon's Returns to Shame
finance.yahoo.com - June 13 at 5:41 PM
americanbankingnews.com logoMaxim Group Analysts Give Inovio Pharmaceuticals Inc (INO) a $12.00 Price Target
www.americanbankingnews.com - June 11 at 8:30 AM
americanbankingnews.com logo$18.75 Million in Sales Expected for Inovio Pharmaceuticals Inc (INO) This Quarter
www.americanbankingnews.com - June 11 at 7:44 AM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Expected to Announce Earnings of -$0.19 Per Share
www.americanbankingnews.com - June 10 at 12:28 AM
finance.yahoo.com logoCramer’s Exec Cut: CEOs examine the power of strategic pa...
finance.yahoo.com - June 9 at 8:24 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Earns Buy Rating from HC Wainwright
www.americanbankingnews.com - June 9 at 7:38 PM
finance.yahoo.com logoInovio's HPV Immunotherapy Moves to Phase III, Stock Rises
finance.yahoo.com - June 9 at 9:32 AM
benzinga.com logoFDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study - Benzinga
www.benzinga.com - June 8 at 11:58 PM
fool.com logoWhy Inovio Pharmaceuticals, Inc. Is Rising Today - Motley Fool
www.fool.com - June 8 at 11:58 PM
finance.yahoo.com logoInovio Pharmaceuticals: Cramer's Top Takeaways
finance.yahoo.com - June 8 at 11:58 PM
finance.yahoo.com logoBiotech Movers: NewLink, Inovio, Juno
finance.yahoo.com - June 8 at 6:52 PM
finance.yahoo.com logoWhy Inovio Pharmaceuticals, Inc. Is Rising Today
finance.yahoo.com - June 8 at 6:52 PM
americanbankingnews.com logoInovio Pharmaceuticals Inc (INO) Upgraded to Overweight by Piper Jaffray Companies
www.americanbankingnews.com - June 8 at 12:22 PM
feeds.benzinga.com logoFDA Removes Clinical Hold On Inovio Pharma's VGX-3100, Its First Drug To Enter A Pivotal Study
feeds.benzinga.com - June 8 at 11:46 AM
finance.yahoo.com logoInovio Begins Phase 3 Clinical Trial of VGX-3100 for the Treatment of HPV-Related Cervical Pre-Cancer 
finance.yahoo.com - June 8 at 6:07 AM

Social

Chart

Inovio Pharmaceuticals (INO) Chart for Friday, July, 28, 2017

This page was last updated on 7/28/2017 by MarketBeat.com Staff